The Japan Human Organoids Market was valued at $34.4 Million in 2024 and projected to reach to $72.2 Million by 2029, representing a compound annual growth rate of 16.0%. Japan's human organoids market is poised for substantial expansion through 2029, driven by the nation's commitment to regenerative medicine innovation and precision healthcare solutions.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
Japan's human organoids market reached $34.4 million in 2024 with a projected CAGR of 16%, significantly outpacing the global growth rate of 14.4%, demonstrating Japan's accelerating adoption of organoid technologies.
Japan's government has prioritized regenerative medicine through substantial funding initiatives and regulatory frameworks, positioning the nation as a leading hub for organoid research alongside established biotech clusters in Tokyo and Osaka.
Japan's robust pharmaceutical industry is increasingly integrating organoid models into drug discovery and development pipelines, leveraging precision medicine applications to enhance clinical efficacy and reduce time-to-market.
The market is anticipated to double in value to $72.2 million by 2029, reflecting growing commercialization of organoid-based therapies and expanding applications in disease modeling and personalized medicine across Japanese healthcare institutions.
| COMPANY | USE CASE DESCRIPTION | BENEFITS |
|---|---|---|
|
|
AstraZeneca researchers acquired an adult stem cell-derived human small intestinal organoid model from the HUB biobank. They used it to evaluate toxicity associated with oral oncology drugs. | Organoid response data were integrated into mathematical models to predict intestinal injury and clinical diarrhea, supporting investigation of drug dosing and schedules. |
|
|
Roche (Genentech) purchased patient-derived colorectal cancer organoids PDM95, PDM96, and PDM2674 from ATCC. | Provided access to established human colorectal cancer models for experimental studies, avoiding the need to derive each model from fresh patient samples. |
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
| Report Metric | Details |
|---|---|
| Base Year | 2024 |
| Fastest Growing Segment | DEVELOPMENTAL BIOLOGY (Application) |
| Forecast Period | 2024-2029 |
| Growth Rate | CAGR of 14.4% from 2024 to 2029 |
| Largest Segment | READY-TO-USE PRODUCTS (Type) |
| Market Size Base Year (Billions) | ~USD 1.19 (2024) |
| Revenue Forecast (Billions) | ~USD 2.33 (2029) |
| Segments Covered | Product, Type, Source, Culture Method, Disease Area, Application, End User |
7 segment dimensions are covered across the global market.
| Segment | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | CAGR (%) |
|---|---|---|---|---|---|---|---|---|---|
| ACADEMIC & RESEARCH INSTITUTES | 8 | 8.9 | 9.9 | 11.1 | 12.6 | 14.4 | 16.5 | 19.2 | 14.2 |
| CROS | 21.1 | 23.5 | 26.5 | 30.1 | 34.4 | 39.7 | 46.2 | 54 | 15.3 |
| OTHER END USERS | 2 | 2.1 | 2.4 | 2.6 | 3 | 3.3 | 3.8 | 4.4 | 13 |
| PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES | 30.2 | 34.2 | 39.1 | 45 | 52.1 | 61 | 71.8 | 85.1 | 16.9 |
| TOTAL | 61.3 | 68.7 | 77.8 | 88.9 | 102.1 | 118.4 | 138.3 | 162.7 | 15.9 |
Japan's human organoids market was valued at $34.4 million in 2024 and is expected to grow to $72.2 million by 2029.
Japan's human organoids market is projected to grow at a compound annual growth rate (CAGR) of 16.0% from 2024 to 2029.
Key drivers include Japan's advanced biotechnology infrastructure, government investment in regenerative medicine, aging population demographics, and increasing pharmaceutical sector adoption of organoid models for drug discovery and disease modeling.
Japan's 16.0% CAGR exceeds the global average of 14.4%, positioning Japan as a high-growth market within the Asia Pacific region for human organoids.
Primary applications in Japan include drug discovery, disease modeling, personalized medicine development, and regenerative medicine research supported by both academic and commercial sectors.
The study involved major activities in estimating the current market size for the human organoids market. Exhaustive secondary research was done to collect information on the human organoids industry. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain using primary research. Different approaches, such as top-down and bottom-up, were employed to estimate the total market size. After that, the market breakup and data triangulation procedures were used to estimate the market size of the segments and subsegments of the human organoids market.
The four steps involved in estimating the market size are
In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to identify and collect information for this study.
In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources were mainly industry experts from the core and related industries and preferred suppliers, manufacturers, distributors, service providers, technology developers, researchers, and organizations related to all segments of this industry’s value chain. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts, C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information as well as assess prospects.
BREAKDOWN OF PRIMARY PARTICIPANTS:

To know about the assumptions considered for the study, download the pdf brochure
Both top-down and bottom-up approaches were used to estimate and validate the human organoids market's total size. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
The research methodology used to estimate the market size includes the following:

After arriving at the overall market size by applying the process mentioned above, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
An organoid is a miniaturized and simplified version of an organ produced in vitro in three dimensions that shows realistic microanatomy. Organoids are derived from one or a few cells from tissue, embryonic stem cells, or induced pluripotent stem cells, which can self-organize in three-dimensional culture owing to their self-renewal and differentiation capacities.
Senior Management
• End User
• Finance/Procurement Department
• R&D Department
MarketsandMarkets offers the following customizations for this market report.
Country Information
Company profiles
Product Analysis
Full forecast, segment splits, and company analysis for all Human Organoids Market.
Customize this report to your needs
Get 10% FREE Customization
Customize This Report